GSK invests a further £38m in amoxicillin plant in Singapore

This is the company's sole manufacturing site for amoxicillin, the API used in antibiotics

GSK is investing an additional £38m (US$58m) in its antibiotic manufacturing plant in Singapore.

The plant on Quality Road, built in 1972, is GSK’s sole manufacturing site for amoxicillin, the API used in antibiotics for bacterial infections.

The new investment will be used to construct an additional downstream isolation facility at the site, which will increase production by 50% and help the company meet the growing demand for antibiotics in emerging markets.

Following an initial investment of £35m in 2012, this latest cash injection at the plant will use enzymatic technology over chemical processes and reduce GSK's carbon footprint by up to 25%.

The improved process involves fewer steps under milder conditions and uses less organic solvents, resulting in the elimination of almost 80% of the organic waste associated with the older chemical process, the company said.

This sustainable approach to the manufacture of amoxicillin is consistent with GSK’s commitment to improve the efficiency of pharmaceutical and fine chemical manufacture in Singapore.

Roger Connor, President of Global Manufacturing and Supply, GSK, said: 'GSK and Singapore have enjoyed a highly-productive partnership for over 50 years. This latest investment in sustainable manufacturing and our recent investment announced in October 2014 for a £19m continuous manufacturing facility in Jurong, which produces one of GSK’s key active pharmaceutical ingredients, demonstrates our commitment to ensuring that patients around the world receive the medicines they need.'